Avalo Therapeutics (AVTX) Liabilities and Shareholders Equity (2014 - 2026)
Avalo Therapeutics posted quarterly Liabilities and Shareholders Equity of $99.9 million for Q1 2026, down 27.89% year-on-year from $138.5 million in Q1 2025, and down 14.23% on a QoQ basis from $116.5 million in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $99.9 million in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 27.89% year-over-year to $99.9 million; the trailing twelve-month figure through Mar 2026 stood at $468.0 million (down 5.64% YoY), and the FY2025 full-year result was $116.5 million, down 22.74% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $99.9 million, down from $116.5 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $150.7 million in Q4 2024 and bottomed at $21.0 million in Q4 2023.
- The 5-year median for Liabilities and Shareholders Equity is $98.5 million (2024), against an average of $80.1 million.
- The widest annual swing landed in 2022, when Liabilities and Shareholders Equity slumped 61.67%; it then surged 618.01% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $33.4 million in 2022, then plunged by 37.08% to $21.0 million in 2023, then soared by 618.01% to $150.7 million in 2024, then dropped by 22.74% to $116.5 million in 2025, then retreated by 14.23% to $99.9 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $99.9 million (Q1 2026), $116.5 million (Q4 2025), and $125.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 99.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 99.89 Mn |
| Dec 31, 2025 | 116.46 Mn |
| Sep 30, 2025 | 125.10 Mn |
| Jun 30, 2025 | 126.58 Mn |
| Mar 31, 2025 | 138.52 Mn |
| Dec 31, 2024 | 150.73 Mn |
| Sep 30, 2024 | 98.46 Mn |
| Jun 30, 2024 | 108.31 Mn |
| Mar 31, 2024 | 123.73 Mn |
| Dec 31, 2023 | 20.99 Mn |
| Sep 30, 2023 | 29.27 Mn |
| Jun 30, 2023 | 24.24 Mn |
| Mar 31, 2023 | 36.24 Mn |
| Dec 31, 2022 | 33.37 Mn |
| Sep 30, 2022 | 36.55 Mn |
| Jun 30, 2022 | 32.22 Mn |
| Mar 31, 2022 | 61.90 Mn |
| Dec 31, 2021 | 80.21 Mn |
| Sep 30, 2021 | 95.36 Mn |
| Jun 30, 2021 | 64.09 Mn |
| Mar 31, 2021 | 63.35 Mn |
| Dec 31, 2020 | 43.76 Mn |
| Sep 30, 2020 | 59.19 Mn |
| Jun 30, 2020 | 69.20 Mn |
| Mar 31, 2020 | 44.12 Mn |
| Dec 31, 2019 | 36.11 Mn |
| Sep 30, 2019 | 57.19 Mn |
| Jun 30, 2019 | 59.62 Mn |
| Mar 31, 2019 | 74.87 Mn |
| Dec 31, 2018 | 70.25 Mn |
| Sep 30, 2018 | 67.61 Mn |
| Jun 30, 2018 | 62.15 Mn |
| Mar 31, 2018 | 65.36 Mn |
| Dec 31, 2017 | 42.81 Mn |
| Sep 30, 2017 | 28.20 Mn |
| Jun 30, 2017 | 6.05 Mn |
| Mar 31, 2017 | 3.56 Mn |
| Dec 31, 2016 | 5.77 Mn |
| Sep 30, 2016 | 9.58 Mn |
| Jun 30, 2016 | 13.17 Mn |
| Mar 31, 2016 | 16.93 Mn |
| Dec 31, 2015 | 21.66 Mn |
| Sep 30, 2015 | 5.45 Mn |
| Dec 31, 2014 | 12.32 Mn |